Why the study?
Data remain scarce on the impact of angiotensin system inhibitors on patients with esophageal squamous cell carcinoma undergoing neoadjuvant therapy.
Does incidental use of angiotensin system inhibitors improve survival and pathological response in patients with esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy?
Population
391 ESCC patients who underwent neoadjuvant therapy followed by R0 resection
Comparison
Incidental ASI use vs non-use during neoadjuvant chemotherapy
Design
Retrospective study
Key result
Incidental use of angiotensin system inhibitors during neoadjuvant chemotherapy for ESCC was associated with improved overall survival (HR 0.48; 95% CI 0.29-0.79; p=0.004) and higher MPR (31.3% vs 17.0%).
Authors
Loading...
May support adjunctive angiotensin system inhibitor use in neoadjuvant ESCC; hypothesis-generating and requires prospective trials before practice change.
Cohort (n=391)
Does incidental use of angiotensin system inhibitors improve survival and pathological response in patients with esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy?
Incidental use of angiotensin system inhibitors during neoadjuvant chemotherapy for esophageal squamous cell carcinoma is associated with improved pathological response and long-term survival.
Effect estimate: HR 0.48 (95% CI 0.29-0.79)
p-value: p=0.004
Chen et al. (2026) conducted a cohort in Esophageal squamous cell carcinoma (n=391). Angiotensin system inhibitors (ASIs) vs. Non-users was evaluated on Overall survival (HR 0.48, 95% CI 0.29-0.79, p=0.004). Incidental use of angiotensin system inhibitors during neoadjuvant chemotherapy for ESCC was associated with improved overall survival (HR 0.48; 95% CI 0.29-0.79; p=0.004) and higher MPR (31.3% vs 17.0%).